233 related articles for article (PubMed ID: 33428098)
1. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Borrirukwisitsak S; Tantayakom P; Katchamart W
Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
[TBL] [Abstract][Full Text] [Related]
2. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
5. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
[TBL] [Abstract][Full Text] [Related]
7. Role of rituximab in the treatment of systemic sclerosis: A literature review.
Yoshifuji H; Yomono K; Yamano Y; Kondoh Y; Yasuoka H
Mod Rheumatol; 2023 Nov; 33(6):1068-1077. PubMed ID: 37053127
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
9. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP
Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
11. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
Tang R; Yu J; Shi Y; Zou P; Zeng Z; Tang B; Wang Y; Ling G; Luo M; Xiao R
Int Immunopharmacol; 2020 Jun; 83():106389. PubMed ID: 32172205
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.
Xing NS; Fan GZ; Yan F; Liu YP; Zhang R
Int Immunopharmacol; 2021 Jun; 95():107524. PubMed ID: 33721757
[TBL] [Abstract][Full Text] [Related]
14. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.
de Figueiredo Caldas MMV; de Azevedo KPM; de França Nunes AC; de Oliveira VH; Pimenta IDSF; de Araújo IDT; Neto FAB; da Silveira Gonçalves de Oliveira AK; Piuvezam G
Adv Rheumatol; 2021 Feb; 61(1):15. PubMed ID: 33640020
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
16. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Macrea M; Ghazipura M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Feb; 21(2):317-327. PubMed ID: 37772987
[No Abstract] [Full Text] [Related]
18. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
[TBL] [Abstract][Full Text] [Related]
19. Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Asano Y; Oba K; Sato S
J Dermatol; 2020 Jul; 47(7):796-800. PubMed ID: 32383266
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
